Charles Schwab
MRNA icon

Charles Schwab’s Moderna MRNA Stock Holding History

Charles Schwab’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339M Buy
4,838,884
+104,528
+2% +$5.41M 0.05% 320
2026
Q1 		$241M Buy
4,734,356
+112,798
+2% +$5.26M 0.04% 369
2025
Q4 		$136M Buy
4,621,558
+309,126
+7% +$8.4M 0.02% 569
2025
Q3 		$111M Buy
4,312,432
+1,272,315
+42% +$35.5M 0.02% 654
2025
Q2 		$83.9M Buy
3,040,117
+410,252
+16% +$10.8M 0.01% 759
2025
Q1 		$74.6M Buy
2,629,865
+285,662
+12% +$10.1M 0.01% 810
2024
Q4 		$97.5M Buy
2,344,203
+211,426
+10% +$10.1M 0.02% 682
2024
Q3 		$143M Buy
2,132,777
+83,082
+4% +$7.63M 0.03% 487
2024
Q2 		$243M Buy
2,049,695
+82,106
+4% +$10.4M 0.05% 327
2024
Q1 		$210M Buy
1,967,589
+96,190
+5% +$9.7M 0.05% 340
2023
Q4 		$186M Buy
1,871,399
+70,368
+4% +$5.92M 0.05% 339
2023
Q3 		$186M Buy
1,801,031
+48,851
+3% +$5.45M 0.05% 314
2023
Q2 		$213M Sell
1,752,180
-40,127
-2% -$5.35M 0.06% 275
2023
Q1 		$275M Buy
1,792,307
+33,844
+2% +$5.58M 0.08% 209
2022
Q4 		$316M Buy
1,758,463
+8,824
+0.5% +$1.44M 0.1% 185
2022
Q3 		$207M Buy
1,749,639
+114,077
+7% +$17.3M 0.07% 241
2022
Q2 		$234M Buy
1,635,562
+12,025
+0.7% +$1.72M 0.08% 238
2022
Q1 		$280M Buy
1,623,537
+50,051
+3% +$8.43M 0.08% 216
2021
Q4 		$400M Buy
1,573,486
+35,670
+2% +$10.4M 0.12% 155
2021
Q3 		$592M Buy
1,537,816
+730,049
+90% +$269M 0.19% 95
2021
Q2 		$190M Buy
807,767
+26,621
+3% +$4.76M 0.06% 279
2021
Q1 		$102M Buy
781,146
+46,203
+6% +$6.7M 0.04% 444
2020
Q4 		$76.8M Buy
734,943
+18,423
+3% +$1.86M 0.03% 541
2020
Q3 		$50.7M Sell
716,520
-739,495
-51% -$51.6M 0.02% 660
2020
Q2 		$93.5M Buy
1,456,015
+438,140
+43% +$24M 0.05% 372
2020
Q1 		$30.5M Buy
1,017,875
+176,099
+21% +$4.05M 0.02% 733
2019
Q4 		$16.5M Buy
841,776
+22,702
+3% +$403K 0.01% 1352
2019
Q3 		$13M Buy
+819,074
New +$12.1M 0.01% 1426

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Charles Schwab's MRNA Position: Q2 2026 in Review

Charles Schwab increased its Moderna (MRNA) stake by 2.2% in Q2 2026, buying an estimated $5.41M and bringing the position to 4,838,884 shares worth $339M. The position accounts for 0.05% of the portfolio, ranked #320.

Charles Schwab first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $592M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Charles Schwab held 4,838,884 shares of Moderna worth $339M as of Q2 2026.
  • Charles Schwab bought 104,528 Moderna shares in Q2 2026, an estimated $5.41M.
  • Moderna made up 0.05% of Charles Schwab's portfolio in Q2 2026, its #320 holding.
  • Charles Schwab first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • Charles Schwab's Moderna position peaked at $592M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.